Cell-Based Luciferase Assay for Testing SARS-CoV-2 3CL Protease Inhibitors
A cell-based screening system for viral protease inhibitors was developed using firefly luciferase fragment complementation and validated on the SARS-CoV-2 3CLpro model. The optimal luciferase variant incorporating the VLQSGF proteolytic site (Luc III) retained 88% of its native activity. A critical...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
MDPI AG
2026-04-01
|
| Rangatū: | Biosensors |
| Ngā marau: | |
| Urunga tuihono: | https://www.mdpi.com/2079-6374/16/5/253 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|